Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
People with college education, gay and bisexual men, and people who struggle to make clinic visits were more likely to prefer the long-acting option.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Advocates say the move is more politics than science.
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?